Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis

Current Opinion in HIV and AIDS

Volumn 7, Issue 3, 2012, Pages 268-275

  Geldmacher, Christof ^a   Zumla, Alimuddin ^b   Hoelscher, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

CD4 T cell; HIV; tuberculosis

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL RENEWAL; CELLULAR IMMUNITY; DENDRITIC CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION SENSITIVITY; INTERPHASE; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE PROLIFERATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; TUBERCULOSIS; VIRUS REACTIVATION; VIRUS REPLICATION;

AFRICA, SOUTHERN; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; HIV INFECTIONS; HIV-1; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84859882701     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283524e32     Document Type: Review

References (71)

1. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313:523-526. (Pubitemid 44148457)
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871. (Pubitemid 13080157)
3. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-503. (Pubitemid 14134741)
4. UNAIDS. Epidemiologic update 2010. http://www.unaids.org/globalreport. [Accessed 22 November 2011].
5. WHO. Global tuberculosis control 2011. http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf. [Accessed 22 November 2011].
6. Cohen T, Murray M, Wallengren K, et al. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 2010; 7:e1000296.
7. Houben RM, Crampin AC, Ndhlovu R, et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int J Tuberc Lung Dis 2011; 15:24-31.
8. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150-158. (Pubitemid 40096371)
9. Glynn JR, Murray J, Bester A, et al. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 2008; 22:1859-1867.
10. Diedrich CR, Mattila JT, Klein E, et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 2010; 5:e9611.
11. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27:393-422.
12. Reece ST, Kaufmann SH. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol 2012; 15:63-70.
13. Wolf AJ, Linas B, Trevejo-Nunez GJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007; 179:2509-2519.
14. Reiley WW, Calayag MD, Wittmer ST, et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A 2008; 105:10961-10966.
15. Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4 T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 2001; 69:2666-2674. (Pubitemid 32239743)
16. Egen JG, Rothfuchs AG, Feng CG, et al. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 2011; 34:807-819.
17. Gallegos AM, Pamer EG, Glickman MS. Delayed protection by ESAT-6- specific effector CD4 T cells after airborne M. tuberculosis infection. J Exp Med 2008; 205:2359-2368.
18. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561-572.
19. Gallegos AM, van Heijst JW, Samstein M, et al. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011; 7:e1002052.
20. Huynh KK, Joshi SA, Brown EJ. A delicate dance: host response to mycobacteria. Curr Opin Immunol 2011; 23:464-472.
21. Egen JG, Rothfuchs AG, Feng CG, et al. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 2008; 28:271-284.
22. Caruso AM, Serbina N, Klein E, et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162:5407-5416. (Pubitemid 29307149)
23. Saunders BM, Frank AA, Orme IM, Cooper AM. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65-72. (Pubitemid 35193446)
24. Mogues T, Goodrich ME, Ryan L, et al. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193:271-280. (Pubitemid 32524511)
25. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19:491-494. (Pubitemid 28518024)
26. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008; 8:601-611.
27. Shen Y, Shen L, Sehgal P, et al. Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol 2004; 78:14023-14032. (Pubitemid 39612798)
28. Chen CY, Huang D, Wang RC, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009; 5: e1000392.
29. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011; 15:571-581.
30. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116. (Pubitemid 27450659)
31. Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011; 32:131-137.
32. CavarelliM, Scarlatti G. Phenotype variation in human immunodeficiency virus type 1 transmission and disease progression. Dis Markers 2009; 27:121-136.
33. Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009; 23:147-160.
34. Nishimura Y, Igarashi T, Donau OK, et al. Highly pathogenic SHIVs and SIVs target different CD4 T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci U S A 2004; 101:12324-12329. (Pubitemid 39145442)
35. Veazey RS, Mansfield KG, Tham IC, et al. Dynamics of CCR5 expression by CD4 T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 2000; 74:11001-11007. (Pubitemid 32223965)
36. Picker LJ, Hagen SI, Lum R, et al. Insufficient production and tissue delivery of CD4 memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 2004; 200:1299-1314. (Pubitemid 39552571)
37. Lin PL, Pawar S, Myers A, et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 2006; 74:3790-3803. (Pubitemid 43993310)
38. Maier R, Bartolome-Rodriguez MM, Moulon C, et al. Kinetics of CXCR4 and CCR5 up-regulation and human immunodeficiency virus expansion after antigenic stimulation of primary CD4 T lymphocytes. Blood 2000; 96:1853-1856. (Pubitemid 30661070)
39. Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4 T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-1097. (Pubitemid 40663481)
40. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4 T cells depletes gut lamina propria CD4 T cells. Nature 2005; 434:1148-1152. (Pubitemid 40663495)
41. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4 T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761-770. (Pubitemid 39299462)
42. Brenchley JM, Schacker TW, Ruff LE, et al. CD4 T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759. (Pubitemid 39299461)
43. Okoye A, Meier-Schellersheim M, Brenchley JM, et al. Progressive CD4 central memory T cell decline results in CD4 effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 2007; 204:2171-2185. (Pubitemid 47360877)
44. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18:399-405. (Pubitemid 43947575)
45. Ganesan A, Chattopadhyay PK, Brodie TM, et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 2010; 201:272-284.
46. Biancotto A, Iglehart SJ, Vanpouille C, et al. HIV-1 induced activation of CD4 T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008; 111:699-704.
47. Jambo KC, Sepako E, Fullerton DG, et al. Bronchoalveolar CD4 T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax 2011; 66:375-382.
48. Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009; 180:1262-1270.
49. Knox KS, Vinton C, Hage CA, et al. Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy. J Virol 2010; 84:9010-9018.
50. Diedrich CR, Flynn JL. HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 2011; 79:1407-1417.
51. de Noronha AL, Bafica A, Nogueira L, et al. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract 2008; 204:155-161.
52. Shen JY, Barnes PF, Rea TH, Meyer PR. Immunohistology of tuberculous adenitis in symptomatic HIV infection. Clin Exp Immunol 1988; 72:186-189.
53. Bezuidenhout J, Roberts T, Muller L, et al. Pleural tuberculosis in patients with early HIV infection is associated with increased TNF-alpha expression and necrosis in granulomas. PLoS One 2009; 4:e4228.
54. Geldmacher C, Koup RA. Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection. Trends Immunol. 2012. [Epub ahead of print]
55. Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirusspecific CD4 T cell responses in human immunodeficiency virus type 1- infected patients with high CD4 T cell counts and recurrent retinitis. J Infect Dis 2001; 183:1285-1289. (Pubitemid 32281571)
56. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus- specific CD4 T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4:953-956. (Pubitemid 28364037)
57. Bronke C, Palmer NM, Jansen CA, et al. Dynamics of cytomegalovirus (CMV)- specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005; 191:873-880. (Pubitemid 40349801)
58. Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010; 207:2869-2881.
59. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590-1598.
60. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271-1278. (Pubitemid 126449644)
61. Finberg RW, Wahl SM, Allen JB, et al. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991; 252:1703-1705. (Pubitemid 21917091)
62. Cheynier R, Gratton S, Halloran M, et al. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nat Med 1998; 4:421-427. (Pubitemid 28212757)
63. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155:996-1003. (Pubitemid 27133415)
64. Hoshino Y, Nakata K, Hoshino S, et al. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med 2002; 195:495-505. (Pubitemid 34461302)
65. Lore K, Smed-Sorensen A, Vasudevan J, et al. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4 T cells. J Exp Med 2005; 201:2023-2033. (Pubitemid 41002937)
66. Ulrichs T, Kosmiadi GA, Jorg S, et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J Infect Dis 2005; 192:89-97. (Pubitemid 40863861)
67. Schuetz A, Haule A, Reither K, et al. Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo. PLoS One 2011; 6:e27284.
68. Mattila JT, Diedrich CR, Lin PL, et al. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 2011; 186:3527-3537.
69. Ehlers S. Lazy dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 2009; 37:87-95.
70. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845-855.
71. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588-1598.